Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor.

[1]  P Smith,et al.  FACTOR VII-PHOSPHOLIPID COMPLEX IN MALE SURVIVIRS OF ACUTE MYCORDIAL INFARCTION , 2009, Thrombosis and Haemostasis.

[2]  S. Humphries,et al.  Genetic Determination of Coagulation Factor VIIc Levels among Healthy Middle-aged Women , 1995, Thrombosis and Haemostasis.

[3]  T. van der Poll,et al.  Complete Inhibition of Endotoxin-Induced Coagulation Activation in Chimpanzees with a Monoclonal Fab Fragment against Factor VII/VIIa , 1995, Thrombosis and Haemostasis.

[4]  W. Kisiel,et al.  Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent. , 1994, Blood.

[5]  J Jesty,et al.  Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. , 1994, Biochemistry.

[6]  W. Ruf.  Factor VIIa residue Arg290 is required for efficient activation of the macromolecular substrate factor X. , 1994, Biochemistry.

[7]  M. Ultsch,et al.  Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site. , 1994, Biochemistry.

[8]  T. Luther,et al.  Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. , 1994, The Journal of clinical investigation.

[9]  D. Stuart,et al.  Crystal structure of the extracellular region of human tissue factor , 1994, Nature.

[10]  J. Reiber,et al.  Relation of Plasma Coagulation Factor VII and Fibrinogen to Carotid Artery Intima-Media Thickness , 1994, Thrombosis and Haemostasis.

[11]  P. Mannucci,et al.  Repeated Release of the Tissue Factor Pathway Inhibitor , 1994, Thrombosis and Haemostasis.

[12]  K. Duffin,et al.  Heterogeneity of plasma tissue factor pathway inhibitor. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[13]  J. Schullek,et al.  Key ligand interface residues in tissue factor contribute independently to factor VIIa binding. , 1994, The Journal of biological chemistry.

[14]  S. Iwanaga,et al.  Identification of regions of bovine factor VII essential for binding to tissue factor. , 1994, The Journal of biological chemistry.

[15]  P. Ostergaard,et al.  Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. , 1994, Thrombosis research.

[16]  C. Figueroa,et al.  Assembly of contact-phase factors on the surface of the human neutrophil membrane , 1994 .

[17]  A. Schwartz,et al.  The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Petersen,et al.  Involvement of the hydrophobic stack residues 39–44 of factor VIIa in tissue factor interactions , 1994, FEBS letters.

[19]  T. Koyama,et al.  Determination of plasma tissue factor antigen and its clinical significance , 1994, British journal of haematology.

[20]  A. Folsom,et al.  Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[21]  W. Kisiel,et al.  Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Meade,et al.  Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease , 1994, The Lancet.

[23]  J. Schullek,et al.  Mutational mapping of functional residues in tissue factor: identification of factor VII recognition determinants in both structural modules of the predicted cytokine receptor homology domain. , 1994, Biochemistry.

[24]  B. Lindblad,et al.  Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparin. , 1994, Thrombosis and haemostasis.

[25]  J. Cooper,et al.  Dietary fat induces changes in factor VII coagulant activity through effects on plasma free stearic acid concentration. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[26]  S. Humphries,et al.  Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[27]  K. Kario,et al.  Fluorogenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[28]  K. Kario,et al.  Factor VII hyperactivity and ischaemic heart disease , 1994, The Lancet.

[29]  W. Novotny.  Tissue Factor Pathway Inhibitor , 1994, Seminars in thrombosis and hemostasis.

[30]  G. Broze,et al.  Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. , 1993, The Journal of biological chemistry.

[31]  J. Harenberg,et al.  Protamine Neutralization of the Release of Tissue Factor Pathway Inhibitor Activity by Heparins , 1993, Thrombosis and Haemostasis.

[32]  B. Lindblad,et al.  Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis. , 1993, Thrombosis research.

[33]  S. Rapaport,et al.  Studies of factor Xa/phospholipid-induced intravascular coagulation in rabbits. Effects of immunodepletion of tissue factor pathway inhibitor. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[34]  P. Neuenschwander,et al.  Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. , 1993, The Journal of biological chemistry.

[35]  L. Poller,et al.  The inter‐relationship of factor VII and its activity state with plasma lipids in healthy male adults , 1993, British journal of haematology.

[36]  R. Wesselschmidt,et al.  Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[37]  A. Kumar,et al.  Specific molecular interaction sites on factor VII involved in factor X activation. , 1993, European journal of biochemistry.

[38]  O. Nordfang,et al.  Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[39]  O. Svendsen,et al.  The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[40]  T. Olivecrona,et al.  Depletion of lipoprotein lipase after heparin administration. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[41]  M. Levi,et al.  The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. , 1993, The Journal of clinical investigation.

[42]  G. Broze,et al.  Inhibition of factor VIIa/tissue factor by antithrombin III and tissue factor pathway inhibitor. , 1993, Blood.

[43]  W. Kisiel,et al.  Isolation and characterization of proteolytic fragments of human factor VIIa which inhibit the tissue factor-enhanced amidolytic activity of factor VIIa. , 1993, The Journal of biological chemistry.

[44]  O. Nordfang,et al.  Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae. , 1993, The Journal of biological chemistry.

[45]  A. Chang,et al.  Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. , 1993, The Journal of clinical investigation.

[46]  S. Rapaport,et al.  Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa , 1993 .

[47]  R. Ornberg,et al.  Prevention of Thrombosis by Topical Application of Tissue Factor Pathway Inhibitor in a Rabbit Model of Vascular Trauma , 1993, Annals of plastic surgery.

[48]  W. Kisiel,et al.  Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces. , 1993, The Journal of biological chemistry.

[49]  U. Hedner,et al.  Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. , 1993, Transfusion medicine reviews.

[50]  W. Kisiel,et al.  Distribution of Tissue Factor Pathway Inhibitor in Normal and Malignant Human Tissues , 1993, Thrombosis and Haemostasis.

[51]  Steven D. Carson,et al.  The role of tissue factor in the production of thrombin. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[52]  S. Rapaport,et al.  Heparin-Releasable and Platelet Pools of Tissue Factor Pathway Inhibitor in Rabbits , 1993, Thrombosis and Haemostasis.

[53]  F. Manzato,et al.  Levels of plasma factor VII and factor VII activated forms as a function of plasma triglyceride levels. , 1993, Atherosclerosis.

[54]  P. Comp,et al.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation , 1993 .

[55]  K. Mann,et al.  Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. , 1993, The Journal of biological chemistry.

[56]  J. Birktoft,et al.  Identification of a calcium binding site in the protease domain of human blood coagulation factor VII: evidence for its role in factor VII-tissue factor interaction. , 1993, Biochemistry.

[57]  M. McGee,et al.  Diffusion control in blood coagulation. Activation of factor X by factors IXa/VIIIa assembled on human monocyte membranes. , 1992, The Journal of biological chemistry.

[58]  D. Welsch,et al.  Bacterial expression, purification, and partial characterization of amino acids 94-155 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation factor Xa. , 1992, Thrombosis research.

[59]  K. Mann,et al.  The role of the membrane in the expression of the vitamin K-dependent enzymes. , 1992, Archives of pathology & laboratory medicine.

[60]  S Krishnaswamy,et al.  The interaction of human factor VIIa with tissue factor. , 1992, The Journal of biological chemistry.

[61]  W. Kisiel,et al.  Tissue factor-dependent autoactivation of human blood coagulation factor VII. , 1992, The Journal of biological chemistry.

[62]  G. Broze,et al.  The asparagine-linked oligosaccharides on tissue factor pathway inhibitor terminate with SO4-4GalNAc beta 1, 4GlcNAc beta 1,2 Mana alpha. , 1992, The Journal of biological chemistry.

[63]  S. Iwanaga,et al.  Tissue factor potentiates the factor VIIa-catalyzed hydrolysis of an ester substrate. , 1992, The Journal of biological chemistry.

[64]  A. Lindahl,et al.  The present status of tissue factor pathway inhibitor. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[65]  P. Neuenschwander,et al.  Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity. , 1992, The Journal of biological chemistry.

[66]  A. Wilson,et al.  Clearance of Recombinant Tissue Factor Pathway Inhibitor (TFPI) in Rabbits , 1992, Thrombosis and Haemostasis.

[67]  Y. Nemerson,et al.  Measurement of basal levels of factor VIIa in hemophilia A and B patients. , 1992, Blood.

[68]  T. Wun,et al.  Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis. , 1992, Journal of pharmacological and toxicological methods.

[69]  S. Basu,et al.  Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. , 1992, Blood.

[70]  A. Hoang,et al.  Factor Vlla/Tissue Factor-Catalyzed Activation of Factors IX and X on a Cell Surface and in Suspension: A Kinetic Study , 1992, Thrombosis and Haemostasis.

[71]  W. Kisiel,et al.  The Role of Phospholipids and the Factor VII Gla-Domain in the Interaction of Factor VII with Tissue Factor , 1992, Thrombosis and Haemostasis.

[72]  O. Nordfang,et al.  Effect of Leukocyte Proteinases on Tissue Factor Pathway Inhibitor , 1992, Thrombosis and Haemostasis.

[73]  R. Wesselschmidt,et al.  Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. , 1992, Blood.

[74]  P. Ostergaard,et al.  Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[75]  G. Broze,et al.  The effect of leukocyte elastase on tissue factor pathway inhibitor. , 1992, Blood.

[76]  G. Broze.  Tissue factor pathway inhibitor and the revised hypothesis of blood coagulation. , 1992, Trends in cardiovascular medicine.

[77]  R. Miller,et al.  Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[78]  M. Blajchman,et al.  The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor , 1992, FEBS letters.

[79]  M. Ultsch,et al.  Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. , 1992, Science.

[80]  N. Callander,et al.  Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. , 1992, The Journal of biological chemistry.

[81]  T. Wun,et al.  Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. , 1992, Blood.

[82]  A. Lindahl,et al.  Tissue factor pathway inhibitor with high anticoagulant activity is increased in post‐heparin plasma and in plasma from cancer patients , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[83]  W. Kisiel,et al.  Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. , 1991, Biochemistry.

[84]  L. S. Nielsen,et al.  The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. , 1991, Biochemistry.

[85]  K Fujikawa,et al.  The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.

[86]  T. Wun,et al.  Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas. , 1991, Thrombosis research.

[87]  K. Smith,et al.  Localization of the human tissue factor recognition determinant of human factor VIIa. , 1991, The Journal of biological chemistry.

[88]  A. Lindahl,et al.  The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. , 1991, Thrombosis research.

[89]  P. Ostergaard,et al.  Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[90]  M. Esnouf,et al.  The Autoactivation of Factor XII in the Presence of Long-Chain Saturated Fatty Acids – A Comparison with the Potency of Sulphatides and Dextran Sulphate , 1991, Thrombosis and Haemostasis.

[91]  O. Nordfang,et al.  Inhibition of Extrinsic Pathway Inhibitor Shortens the Coagulation Time of Normal Plasma and of Hemophilia Plasma , 1991, Thrombosis and Haemostasis.

[92]  S. Rapaport,et al.  Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. , 1991, Blood.

[93]  T S Edgington,et al.  Characterization of factor VII association with tissue factor in solution. High and low affinity calcium binding sites in factor VII contribute to functionally distinct interactions. , 1991, The Journal of biological chemistry.

[94]  Burton E. Sobel,et al.  Prevention of Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein‐Associated Coagulation Inhibitor , 1991, Circulation.

[95]  J. Miletich,et al.  Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. , 1991, Blood.

[96]  D. Rader,et al.  Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. , 1991, Blood.

[97]  S. Rapaport.  The Extrinsic Pathway Inhibitor: A Regulator of Tissue Factor-Dependent Blood Coagulation , 1991, Thrombosis and Haemostasis.

[98]  W. Kisiel,et al.  Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine. , 1991, The Journal of biological chemistry.

[99]  A. Hubbard,et al.  Phospholipase C mediated inhibition of factor VII requires triglyceride-rich lipoproteins. , 1991, Thrombosis research.

[100]  T. Meade,et al.  A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[101]  J. Boissel,et al.  Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin , 1991, The British journal of surgery.

[102]  Y. Nemerson,et al.  Factors Affecting the lnteraction of Tissue Factor/Factor Vll with Factor X in a Heterogeneous Tubular Reactor , 1991, Thrombosis and Haemostasis.

[103]  J. Cooper,et al.  Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition. , 1991, Atherosclerosis.

[104]  P. Sandset,et al.  Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[105]  D. Blumenthal,et al.  Identification of molecular sites on factor VII which mediate its assembly and function in the extrinsic pathway activation complex. , 1991, The Journal of biological chemistry.

[106]  H. Saito,et al.  Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[107]  T. Wun,et al.  Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. , 1990, Blood.

[108]  Y Komiyama,et al.  Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. , 1990, Biochemistry.

[109]  K. Norris,et al.  Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. , 1990, The Journal of biological chemistry.

[110]  J. Brozna.  Cellular regulation of tissue factor , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[111]  G. Broze,et al.  Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2. , 1990, The Biochemical journal.

[112]  D. Rifkin,et al.  Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[113]  W. Kisiel,et al.  The importance of residues 195-206 of human blood clotting factor VII in the interaction of factor VII with tissue factor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[114]  W. Novotny,et al.  Regulation of coagulation by a multivalent Kunitz-type inhibitor. , 1990, Biochemistry.

[115]  H. ten Cate,et al.  Factor IX is activated in vivo by the tissue factor mechanism. , 1990, Blood.

[116]  U. Hedner.  Factor VIIa in the treatment of haemophilia. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[117]  A. Giles,et al.  A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model. , 1990, Blood.

[118]  B. Østerud.  Factor VII and haemostasis. , 1990 .

[119]  G. Raskob,et al.  Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. , 1990, The New England journal of medicine.

[120]  S. Rapaport,et al.  Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. , 1990, Blood.

[121]  S. Rapaport,et al.  Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa , 1990 .

[122]  R. Bertina,et al.  The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. , 1990, The Biochemical journal.

[123]  W. Kisiel,et al.  Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl2-Glc) O-glycosidically linked to a serine residue in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z. , 1989, The Journal of biological chemistry.

[124]  L. Petersen,et al.  Autoactivation of human recombinant coagulation factor VII. , 1989, Biochemistry.

[125]  J. Miletich,et al.  Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. , 1989, The Journal of biological chemistry.

[126]  A. Hubbard,et al.  The effect of phospholipase C on plasma factor VII , 1989, British journal of haematology.

[127]  M. Bednarek,et al.  DETECTION OF FACTOR X ACTIVATION IN HUMANS , 1989, Thrombosis and Haemostasis.

[128]  W. Lawson,et al.  Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. , 1989, Journal of the American College of Cardiology.

[129]  P. Sandset,et al.  Extrinsic coagulation pathway inhibitor and heparin cofactor II during normal and hypertensive pregnancy. , 1989, Thrombosis research.

[130]  P. Sandset,et al.  The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. , 1989, Thrombosis research.

[131]  S. Rapaport,et al.  Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. , 1989, Blood.

[132]  A. Lindahl,et al.  High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. , 1989, Acta chirurgica Scandinavica.

[133]  D. Spriggs,et al.  Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. , 1989, Blood.

[134]  S. Rapaport,et al.  Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables. , 1989, Blood.

[135]  P. Sandset,et al.  Factor VII and extrinsic pathway inhibitor in acute coronary disease , 1989, British journal of haematology.

[136]  M. Fournel,et al.  Inactivation of human antithrombin by neutrophil elastase. Kinetics of the heparin-dependent reaction. , 1989, The Journal of biological chemistry.

[137]  L. Lau,et al.  A growth factor-responsive gene of murine BALB/c 3T3 cells encodes a protein homologous to human tissue factor , 1989, Molecular and cellular biology.

[138]  W. Kisiel,et al.  Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells. , 1989, Blood.

[139]  Susan G. Brown,et al.  Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor , 1989, Nature.

[140]  Josiahn . Wilcox,et al.  Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[141]  J. Cruickshank,et al.  Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. , 1989, Atherosclerosis.

[142]  M. Read,et al.  Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[143]  S. Rapaport,et al.  Modifications of Extrinsic Pathway Inhibitor (EPI) and Factor Xa that Affect their Ability to Interact and to Inhibit Factor Vila/Tissue Factor: Evidence for a Two-Step Model of Inhibition , 1988, Thrombosis and Haemostasis.

[144]  J. Miletich,et al.  Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor , 1988 .

[145]  S. Kawabata,et al.  A new trisaccharide sugar chain linked to a serine residue in bovine blood coagulation factors VII and IX. , 1988, Journal of biochemistry.

[146]  L. Thim,et al.  Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. , 1988, Biochemistry.

[147]  D. Altieri,et al.  Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[148]  Y. Nemerson,et al.  Flow as a regulator of the activation of factor X by tissue factor. , 1988, Blood.

[149]  U. Stenman,et al.  Immunofluorometric demonstration and quantification of placental protein 5 in the absence of pregnancy. , 1988, Clinical chemistry.

[150]  K. Mann,et al.  A combination of factor Xa and phosphatidylcholine‐phosphatidylserine vesicles bypasses factor VIII in vivo , 1988, British journal of haematology.

[151]  M. L. Larsen,et al.  Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). , 1988, Thrombosis research.

[152]  J. Miletich,et al.  Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. , 1988, The Journal of biological chemistry.

[153]  M. Hultin,et al.  Factor VII activity state in coronary artery disease. , 1988, The Journal of laboratory and clinical medicine.

[154]  J. Miletich,et al.  The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action , 1988 .

[155]  S. Rapaport,et al.  Partial purification and characterization of extrinsic pathway inhibitor (the factor Xa-dependent plasma inhibitor of factor VIIa/tissue factor). , 1987, Thrombosis research.

[156]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[157]  J. Miletich,et al.  Human tissue factor: cDNA sequence and chromosome localization of the gene. , 1987, Biochemistry.

[158]  T. Edgington,et al.  Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade , 1987, Cell.

[159]  S. Bajaj,et al.  INHIBITOR OF THE FACTOR VIIA-TISSUE FACTOR COMPLEX IS REDUCED IN PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION BUT NOT IN PATIENTS WITH SEVERE HEPATOCELLULAR DISEASE , 1987, Thrombosis and Haemostasis.

[160]  A. Hubbard,et al.  Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. , 1987, Thrombosis research.

[161]  T W Meade,et al.  Hypercoagulability and ischaemic heart disease. , 1987, Blood reviews.

[162]  F. Rickles,et al.  Activation of blood coagulation in Crohn's disease. Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity. , 1987, Gastroenterology.

[163]  S. Rapaport,et al.  Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. , 1987, Blood.

[164]  V. Kakkar,et al.  Preventive and therapeutic approach to venous thromboembolic disease and pulmonary embolism--can death from pulmonary embolism be prevented? , 1986, Journal of the American College of Cardiology.

[165]  G. Raskob,et al.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. , 1986, The New England journal of medicine.

[166]  J. Hirsh,et al.  A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. , 1986, The New England journal of medicine.

[167]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[168]  Y. Nemerson,et al.  Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. , 1986, Biochemistry.

[169]  Y. Nemerson,et al.  An ordered addition, essential activation model of the tissue factor pathway of coagulation: evidence for a conformational cage. , 1986, Biochemistry.

[170]  A. Hubbard,et al.  Inhibition of tissue thromboplastin-mediated blood coagulation. , 1986, Thrombosis research.

[171]  G. Assmann,et al.  Epidemiological Study on Factor VII, Factor VIII and Fibrinogen in an Industrial Population - II. Baseline Data on the Relation to Blood Pressure, Blood Glucose, Uric Acid, and Lipid Fractions , 1985, Thrombosis and Haemostasis.

[172]  I. Hjermann,et al.  A novel form of factor VII in plasma from men at risk for cardiovascular disease , 1985, British journal of haematology.

[173]  J. Miletich,et al.  Purification of human brain tissue factor. , 1985, The Journal of biological chemistry.

[174]  S. Rapaport,et al.  Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. , 1985, Blood.

[175]  S. Thompson,et al.  Assay of factor VII activity by two techniques: evidence for increased conversion of VII to αVIIa in hyperlipidaemia, with possible implications for ischaemic heart disease , 1985, British journal of haematology.

[176]  K. Mann,et al.  Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation. , 1984, The Journal of clinical investigation.

[177]  L. Wilhelmsen,et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.

[178]  K. Kurachi,et al.  Characterization of a cDNA coding for human factor VII. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[179]  D. Fair.  Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. , 1983, Blood.

[180]  T. Chard,et al.  A method for the purification of placental protein 5 (PP5) from placental extracts. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[181]  J. Griffin,et al.  Sulfatide-dependent autoactivation of human blood coagulation Factor XII (Hageman Factor). , 1983, The Journal of biological chemistry.

[182]  W. Kisiel,et al.  Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. , 1983, The Journal of clinical investigation.

[183]  N. Semeraro,et al.  Cultured human endothelial cells generate tissue factor in response to endotoxin. , 1983, The Journal of clinical investigation.

[184]  K. Bauer,et al.  Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. , 1982, Blood.

[185]  K. Mann,et al.  The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits. , 1982, Blood.

[186]  W. Konigsberg,et al.  Purification and characterization of bovine tissue factor. , 1981, The Journal of biological chemistry.

[187]  W. Kisiel,et al.  Isolation and characterization of human factor VIIa. , 1981, Thrombosis research.

[188]  S. Shapiro,et al.  Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. , 1980, The New England journal of medicine.

[189]  S. Thompson,et al.  HÆMOSTATIC FUNCTION AND CARDIOVASCULAR DEATH: EARLY RESULTS OF A PROSPECTIVE STUDY , 1980, The Lancet.

[190]  P. Majerus,et al.  Purification and properties of human coagulation factor VII. , 1980, The Journal of biological chemistry.

[191]  B. Osterud,et al.  Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. , 1979, Blood.

[192]  B. Osterud,et al.  Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII. , 1978, Blood.

[193]  A. J. Robinson,et al.  Procoagulant activity of peritoneal leukocytes: effects of cortisone and endotoxin. , 1978, The American journal of physiology.

[194]  K. Fujikawa,et al.  Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). , 1977, Biochemistry.

[195]  Y. Nemerson,et al.  Mechanism of activation of bovine factor VII. Products of cleavage by factor Xa. , 1976, The Journal of biological chemistry.

[196]  F. Pitlick.  Binding of bovine brain tissue factor to concanavalin A-Sepharose. Partial purification of coagulant, arylamidase, and alkaline phosphatase activities. , 1976, Biochimica et biophysica acta.

[197]  W. Weston,et al.  The Endotoxin‐induced Coagulant Activity of Human Monocytes , 1975, British journal of haematology.

[198]  V. Kakkar.  Deep Vein Thrombosis: Detection and Prevention , 1975 .

[199]  Oxon Dm.  Obituary. Rupert Samuel Bruce Pearson. , 1974 .

[200]  Maddocks Ac.  Letter: Sterilisation of cardiac bioptome. , 1974 .

[201]  K. Wuepper,et al.  ACTIVATION OF HAGEMAN FACTOR IN SOLID AND FLUID PHASES , 1973, The Journal of experimental medicine.

[202]  H. Prydz,et al.  Studies on Tissue Thromboplastin - Its Splitting into Two Separable Parts , 1969, Thrombosis and Haemostasis.

[203]  B. Lindblad,et al.  Does glycosylation influence the experimental antithrombotic effect of a two-domain tissue factor pathway inhibitor? , 1996, Haemostasis.

[204]  S. Rapaport,et al.  Evidence suggestive of activation of the intrinsic pathway of blood coagulation after injection of factor Xa/phospholipid into rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[205]  U. Pendurthi,et al.  Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. , 1995, Blood.

[206]  A. Hofman,et al.  Factor VII coagulant activity is related to blood lipids in the elderly. The Rotterdam study , 1994 .

[207]  M. Blombäck,et al.  Activation of coagulation factor VII during alimentary lipemia. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[208]  H. Hemker,et al.  Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. , 1994, The Biochemical journal.

[209]  D. Monroe,et al.  Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. , 1994, Blood.

[210]  J. Wells,et al.  Structure and function of human growth hormone: implications for the hematopoietins. , 1993, Annual review of biophysics and biomolecular structure.

[211]  C. Esmon,et al.  Cell mediated events that control blood coagulation and vascular injury. , 1993, Annual review of cell biology.

[212]  A. Rehemtulla,et al.  Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. , 1991, The Journal of biological chemistry.

[213]  F. Taylor,et al.  Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. , 1991, Circulatory shock.

[214]  P. Sandset,et al.  Extrinsic pathway inhibitor--the key to feedback control of blood coagulation initiated by tissue thromboplastin. , 1991, Haemostasis.

[215]  C. Soria,et al.  Coagulation Factor VII and Plasma Triglycerides , 1989 .

[216]  P. Sandset,et al.  Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. , 1989, Haemostasis.

[217]  R. Bach.  Initiation of Coagulation by Tissue Facto , 1988 .

[218]  V. Nguyen.  Fibrinogen and risk of cardiovascular disease: Kannel WB, Wolf PA, Castelli WP, et al JAMA 258: 1183–1186 Sep 1987 , 1988 .

[219]  C. Esmon,et al.  Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. , 1987, The Journal of clinical investigation.

[220]  J. Miletich,et al.  Characterization of the inhibition of tissue factor in serum. , 1987, Blood.

[221]  P. Sandset,et al.  EXTRINSIC PATHWAY INHIBITOR (EPI) DURING ELECTUVE SUGERY : A COMPARISON WITH OTHER COAGULATION INHIBITORS , 1987, Thrombosis and Haemostasis.

[222]  Robert W. Colman.  Hemostasis and thrombosis: Basic principles and clinical practice , 1987 .

[223]  G. Mariani,et al.  Factor VII congenital deficiency. Clinical picture and classification of the variants. , 1983, Haemostasis.

[224]  A. Bloom.  Haemostasis and thrombosis , 1981 .

[225]  P. Majerus,et al.  [19] Human factor VII , 1981 .

[226]  M. Scully,et al.  Inhibition Of Human Factor Xa By Various Plasma Protease Inhibitors , 1981, Thrombosis and Haemostasis.

[227]  Y. Nemerson,et al.  The phospholipid requirement of tissue factor in blood coagulation. , 1968, The Journal of clinical investigation.

[228]  H. Hortling,et al.  The nembutal metabolic rate as an aid in the study of thyroid function. , 1957, Scandinavian journal of clinical and laboratory investigation.